Guizhou Bailing Group Pharmaceutical Co., Ltd.
SZSE:002424.SZ
7.99 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 4,262.971 | 3,540.132 | 3,111.65 | 3,087.888 | 2,850.585 | 3,136.843 | 2,591.817 | 2,214.211 | 1,899.088 | 1,574.672 | 1,405.33 | 1,367.582 | 1,138.427 | 863.756 | 734.518 | 607.359 | 446.204 |
Cost of Revenue
| 1,905.774 | 1,411.923 | 1,256.377 | 1,345.124 | 1,136.748 | 1,262.654 | 951.969 | 788.955 | 720.559 | 616.203 | 559.133 | 622.213 | 508.335 | 412.085 | 397.864 | 323.769 | 229.181 |
Gross Profit
| 2,357.197 | 2,128.209 | 1,855.272 | 1,742.764 | 1,713.838 | 1,874.19 | 1,639.847 | 1,425.256 | 1,178.529 | 958.47 | 846.197 | 745.369 | 630.092 | 451.672 | 336.654 | 283.59 | 217.023 |
Gross Profit Ratio
| 0.553 | 0.601 | 0.596 | 0.564 | 0.601 | 0.597 | 0.633 | 0.644 | 0.621 | 0.609 | 0.602 | 0.545 | 0.553 | 0.523 | 0.458 | 0.467 | 0.486 |
Reseach & Development Expenses
| 42.04 | 22.404 | 30.425 | 36.997 | 24.791 | 30.847 | 37.482 | 24.471 | 21.317 | 16.409 | 8.618 | 6.333 | 3.219 | 2.448 | 0 | 0 | 0 |
General & Administrative Expenses
| 82.298 | 78.797 | 59.939 | 78.313 | 60.19 | 46.292 | 43.084 | 39.463 | 38.118 | 43.734 | 25.494 | 30.319 | 23.252 | 22.474 | 40.695 | 39.187 | 24.828 |
Selling & Marketing Expenses
| 2,310.795 | 1,530.376 | 1,288.678 | 1,135.454 | 970.365 | 933.127 | 782.342 | 613.795 | 456.904 | 392.509 | 362.532 | 354.463 | 262.228 | 192.05 | 144.207 | 123.426 | 91.262 |
SG&A
| 2,393.093 | 1,609.173 | 1,348.617 | 1,213.767 | 1,030.554 | 979.418 | 825.426 | 653.258 | 495.023 | 436.243 | 388.027 | 384.781 | 285.48 | 214.525 | 184.902 | 162.613 | 116.09 |
Other Expenses
| -14.513 | 173.121 | 164.121 | 156.224 | 148.605 | 1.572 | -6.217 | 10.395 | 21.584 | 5.792 | 6.647 | 36.765 | 3.749 | 22.331 | 0.653 | -1.748 | 1.09 |
Operating Expenses
| 2,619.352 | 1,804.698 | 1,543.163 | 1,406.988 | 1,203.95 | 1,155.471 | 979.499 | 818.308 | 648.46 | 547.962 | 481.802 | 460.003 | 345.782 | 249.237 | 192.138 | 168.483 | 120.499 |
Operating Income
| -484.417 | 357.964 | 277.905 | 418.793 | 493.254 | 664.252 | 626.416 | 569.902 | 470.634 | 371.529 | 319.9 | 253.737 | 238.325 | 183.232 | 130.809 | 99.41 | 86.396 |
Operating Income Ratio
| -0.114 | 0.101 | 0.089 | 0.136 | 0.173 | 0.212 | 0.242 | 0.257 | 0.248 | 0.236 | 0.228 | 0.186 | 0.209 | 0.212 | 0.178 | 0.164 | 0.194 |
Total Other Income Expenses Net
| -8.653 | -198.908 | -130.147 | -210.023 | -137.507 | -52.894 | -28.144 | -27.005 | -38.169 | -33.401 | -38.236 | -21.982 | -42.338 | -12.878 | -13.065 | -18.271 | -9.038 |
Income Before Tax
| -493.069 | 159.056 | 147.758 | 208.77 | 355.747 | 665.824 | 632.204 | 579.944 | 491.899 | 377.106 | 326.159 | 263.384 | 241.972 | 189.557 | 131.451 | 96.836 | 87.486 |
Income Before Tax Ratio
| -0.116 | 0.045 | 0.047 | 0.068 | 0.125 | 0.212 | 0.244 | 0.262 | 0.259 | 0.239 | 0.232 | 0.193 | 0.213 | 0.219 | 0.179 | 0.159 | 0.196 |
Income Tax Expense
| -80.605 | 23.086 | 31.07 | 55.044 | 71.196 | 94.057 | 100.174 | 93.682 | 75.751 | 62.052 | 53.165 | 34.524 | 31.992 | 31.358 | 19.784 | 16.54 | 15.489 |
Net Income
| -414.511 | 138.474 | 118.483 | 152.375 | 282.749 | 563.239 | 526.137 | 482.327 | 411.375 | 310.478 | 269.604 | 221.752 | 208.381 | 158.198 | 111.667 | 80.296 | 71.905 |
Net Income Ratio
| -0.097 | 0.039 | 0.038 | 0.049 | 0.099 | 0.18 | 0.203 | 0.218 | 0.217 | 0.197 | 0.192 | 0.162 | 0.183 | 0.183 | 0.152 | 0.132 | 0.161 |
EPS
| -0.3 | 0.099 | 0.085 | 0.11 | 0.2 | 0.4 | 0.37 | 0.34 | 0.29 | 0.22 | 0.19 | 0.16 | 0.15 | 0.13 | 0.17 | 0.076 | 0.068 |
EPS Diluted
| -0.3 | 0.099 | 0.085 | 0.11 | 0.2 | 0.39 | 0.37 | 0.34 | 0.29 | 0.22 | 0.19 | 0.16 | 0.15 | 0.12 | 0.17 | 0.076 | 0.068 |
EBITDA
| -163.706 | 474.129 | 384.916 | 515.276 | 581.856 | 850.71 | 737.489 | 700.133 | 642.109 | 501.061 | 433.755 | 393.433 | 343.766 | 233.142 | 159.074 | 126.624 | 109.901 |
EBITDA Ratio
| -0.038 | 0.134 | 0.124 | 0.167 | 0.204 | 0.271 | 0.285 | 0.316 | 0.338 | 0.318 | 0.309 | 0.288 | 0.302 | 0.27 | 0.217 | 0.208 | 0.246 |